Recursion Pharmaceuticals

Recursion Pharmaceuticals Assets per Share

The Total Assets per Share of Recursion Pharmaceuticals (RXRX) as of Nov 20, 2026 is 2.84 USD. In the previous year, Total Assets per Share was 2.79 USD — a change of 1.76% (higher).

Assets per Share

2.84USD

YoY

1.76%

Last updated:

Total Assets per Share of Recursion Pharmaceuticals is 2025 2.84 USD. Total Assets per Share of Recursion Pharmaceuticals was 2024 2.79 USD. It decreases by 1.76% higher compared to the previous year.

The Recursion Pharmaceuticals Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2019
0.20 USD
Jan 1, 2020
0.57 USD
Jan 1, 2021
1.17 USD
Jan 1, 2022
1.35 USD
Jan 1, 2023
1.26 USD
Jan 1, 2024
2.79 USD
Jan 1, 2025
2.84 USD
The Recursion Pharmaceuticals Assets per Share history
YEARAssets per ShareYoY
2.84USD+1.76%
2.79USD+121.60%
1.26USD-6.79%
1.35USD+14.90%
1.17USD+104.41%
0.57USD+194.37%
0.20USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Total Assets per Share of Recursion Pharmaceuticals is 2.84 USD in 2025.

Total Assets per Share of Recursion Pharmaceuticals changed from 2.79 USD to 2.84 USD, representing a 1.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals